Research press release


Nature Medicine

A personalized assay for cystic fibrosis



Jeffrey Beekmanたちは、腸管幹細胞オルガノイドをつくる技術を応用して、さまざまなCFTR遺伝子変異をもつ嚢胞性線維症患者たちから、組織を成長させた。フォルスコリントよばれる化合物を使うと、オルガノイドを肥大させることができたが、CFTR変異をもつ患者では、この肥大が抑えられたり、起こらなかったりする。オルガノイドにCFTR機能を上昇させる薬剤を投与すると、肥大が再び起こるようになり、その定量によって、個人レベルで受容体機能の回復程度を評価できる。


An analytical test to quantify the function of CFTR, a molecular receptor whose dysfunction causes cystic fibrosis, is reported in a study published this week in Nature Medicine. This fast and robust test uses ‘organoids’ derived from patients with cystic fibrosis to facilitate diagnosis, assess drug response and optimize treatment for each individual.

Few tools exist to screen for efficacy of drugs restoring the function of CFTR and the response of cystic fibrosis patients to the drugs.Even for those with the same mutations, treatment can be variable, which poses a challenge for patients and physicians.

Jeffrey Beekman and his colleagues adapt a technique that uses intestinal stem cell organoids to grow tissues from cystic fibrosis individuals with various mutations in the CFTR gene.By using a compound called forskolin, the authors were able to induce swelling of the organoids, which are reduced or lost in patients with CFTR mutations. Treatment of the organoids with drugs that increase CFTR function re-introduces this swelling, which can be quantified to assess restoration of receptor function on an individual basis.

The authors maintain that this quick in vitro assay can easily generate large amounts of cellular data from patients with different clinical phenotypes of cystic fibrosis and may be useful to predict patient drug response, which was found to vary even among individuals carrying the same CFTR mutation.

doi: 10.1038/nm.3201


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。